barlo® dispositivo médico. Clave interna de material: BAR-2025-03-002. Reg. No. 1324C2023 SSA. Las imágenes son con fines ilustrativos. Las imágenes no corresponden a pacientes reales. Referencias: 1. Eccles R, Mejer, Jawad M, et al. Efficacy and safety of an antiviral lota-Carrageenan nasal spray: a randomized, doble-blind, placebo-controlled exploratory study un volunteers with early symptoms of the common cold. Respi Res. 2010;11(1):108. 2. Carragelose" Nasal Sprays and Throat Products. Preclinical and Clinical Evidence of Safety and Effectiveness. Marinomed Biotech. 3. Morokutti-Kurz M, Fröba M, Graf P, et al. lota-carrageenan neutralizes SARS- COV-2 and inhibits viral replication in vitro. Lo2021;16(2):e0237480. 4. Setz C, Große M, Fröba M, et al. lota-Carrageenan Inhibits Replication of the SARS-COV-2 Variants of Concern Omicron BA.1, BA.2BA.5. Nutraceuticals. 2023;3(3):315-328. 5. Figueroa JM, Lombardo ME, Dogliotti A, et al. Efficacy of a Nasal Spray Containing lota-Carrageenanin the Postexposure Prophylaof COVID-19 in Hospital Personnel Dedicated to Patients Care with COVID-19 Disease. Int J Gen Med. 021;14:6277-6286. Reporte las sospechas de reacción adversa al correo: farmacovigilancia@cofepris.gob.mx y farmacovigilancia@m8pharma.com. No permiso de Publicidad: 253300201B1413. Consulta a tu médico.